The selectivity of plinabulin towards TUBB2 over TUBB3 in neural tissue is based on its differential binding and residence time in the CBS of the two isotypes, and could be exploited in order to target cancer cells that are known to overexpress TUBB3 in response to treatment with MTAs, such as Taxol [31]. Here, TUBB3 is linked to cancer.